Tests two experimental clot-blocking drugs against apixaban in atrial fibrillation
Tests REGN7508 and REGN9933 against apixaban in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Key facts
- Where
- Buenos Aires, Ciudad Autonoma de Buenos Aires, Córdoba, Ramos Mejía, Rosario, Santa Fe, and Temperley, ArgentinaSee the 8 sites
- Phase
- Phase 2
Where in Argentina
- STAT Research ArgentinaBuenos Aires, ArgentinaTaking people
- Centro de Investigacion ClinicaCiudad Autonoma de Buenos Aires, ArgentinaTaking people
- Sanatorio Duarte QuirosCórdoba, ArgentinaTaking people
- DIM Clínica PrivadaRamos Mejía, ArgentinaTaking people
- Fundacion Estudios ClinicosRosario, ArgentinaTaking people
- Sanatorio ParqueRosario, ArgentinaTaking people
- Centro de Investigaciones Clinicas del LitoralSanta Fe, ArgentinaTaking people
- Centro de Investigaciones Medicas Temperley (CIMeT)Temperley, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regeneron Pharmaceuticals
- Trial code
- NCT07175428
- Record updated
- 5 November 2026
- Original description
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation.Read full original descriptionShow less
A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS)
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation.
The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots.
The study is looking at several other research questions, including:
* What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Inclusion: Has AF or flutter (paroxysmal or persistent), not felt to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol; Meets one of the following:; CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Thromboembolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve or; CHA2DS2-VA score ≥3 or; CHA2DS2-VA score of 2 and at least 1 enrichment criteria as described in the protocol; Must have an International Normalization Ratio (INR) <2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA).
Exclusion: Has had successful ablation therapy or Left Atrial Appendage (LAA) occlusion/exclusion, or planned ablation or LAA occlusion/exclusion as described in the protocol; Had an ischemic stroke within 2 days prior to randomization; Has a history of central nervous system bleeding within 30 days prior to randomization; Note: Other protocol-defined Inclusion/ Exclusion criteria apply; Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion); Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m\^2 within 30 days prior to randomization or on dialysis or expected to be started as described in the protocol; Has known moderate-to-severe mitral stenosis.